Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2022

View Archived Issues

MKX regulates periodontal ligament homeostasis

HMB-001 bispecific antibody shows promise for treating Glanzmann thrombasthenia

University of Newcastle upon Tyne describes compounds for preventing DNA damage

Ubix Therapeutics presents PROTAC androgen receptor degraders

Dual PI3K-delta/PI3K-gamma inhibitors identified at National Institute of Pharmaceutical R&D Co.

New complement C1s subcomponent inhibitors discovered at Annexon

Mutant SLC6A8 correctors patented by Jnana Therapeutics

Cofilin siRNA, a promising therapy for treatment of hemorrhagic stroke

PSD3 downregulation as new therapeutic strategy against FLD

SETD2 loss promotes tumor metastasis in ccRCC

Studies at CROI show interferons' complex effects, therapeutic potential

Adcentrx and AvantGen partner to discover antibodies for ADC candidates

Therapeutics Solutions reports preclinical data on CampbellCell stem cell therapy for schizophrenia

Novel curcumin derivative, C-0818, inhibits proliferation and induces apoptosis in HCC cells

VDAC1 overexpression tied to ulcerative colitis

Tumor-associated HEVs predict response in melanoma patients receiving anti-PD-1/CTLA-4 combination

Genomic pan-cancer cohort including 25,000 patients identifies organ-specific metastatic patterns

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...